Zacks: Analysts Expect Becton Dickinson and Co (NYSE:BDX) to Post $3.31 EPS

Equities research analysts predict that Becton Dickinson and Co (NYSE:BDX) will announce earnings per share (EPS) of $3.31 for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Becton Dickinson and’s earnings. The lowest EPS estimate is $3.28 and the highest is $3.41. Becton Dickinson and posted earnings per share of $2.93 during the same quarter last year, which suggests a positive year-over-year growth rate of 13%. The firm is expected to issue its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Becton Dickinson and will report full-year earnings of $11.68 per share for the current fiscal year, with EPS estimates ranging from $11.65 to $11.72. For the next year, analysts anticipate that the firm will report earnings of $12.95 per share, with EPS estimates ranging from $12.73 to $13.15. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Becton Dickinson and.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.91 EPS.

A number of equities analysts have issued reports on the company. Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target for the company in a research note on Monday, May 13th. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. UBS Group cut their price target on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. Wells Fargo & Co cut their price target on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research note on Monday, May 13th. Finally, Piper Jaffray Companies cut their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $264.27.

BDX stock traded up $1.41 during mid-day trading on Friday, reaching $247.76. 22,377 shares of the company traded hands, compared to its average volume of 1,076,436. The stock has a market cap of $66.50 billion, a price-to-earnings ratio of 22.52, a P/E/G ratio of 1.84 and a beta of 1.11. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. Becton Dickinson and has a fifty-two week low of $208.62 and a fifty-two week high of $265.87. The firm’s 50 day moving average price is $251.94 and its 200 day moving average price is $244.27.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.77 dividend. The ex-dividend date is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.24%. Becton Dickinson and’s payout ratio is presently 27.97%.

In other news, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the transaction, the executive vice president now owns 12,608 shares in the company, valued at approximately $2,958,845.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Simon D. Campion sold 2,903 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the transaction, the executive vice president now owns 9,408 shares in the company, valued at approximately $2,229,131.52. The disclosure for this sale can be found here. Insiders sold a total of 24,529 shares of company stock worth $5,836,116 in the last 90 days. Company insiders own 0.12% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BDX. Harvest Group Wealth Management LLC bought a new stake in shares of Becton Dickinson and in the 1st quarter worth approximately $25,000. TRUE Private Wealth Advisors bought a new stake in shares of Becton Dickinson and in the 2nd quarter worth approximately $25,000. Hexavest Inc. bought a new stake in shares of Becton Dickinson and in the 2nd quarter worth approximately $28,000. Lipe & Dalton bought a new stake in shares of Becton Dickinson and in the 2nd quarter worth approximately $28,000. Finally, Pinnacle Financial Partners Inc. bought a new stake in shares of Becton Dickinson and in the 1st quarter worth approximately $29,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Strike Price

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.